Abstract
Indicated prevention is currently one of the most promising approaches to fight the individual and societal burden associated with psychosis and particularly schizophrenia. The number of studies is still limited, yet encouraging results have been reported from pharmacological and psychotherapeutic trials. Furthermore, it has become clear that persons characterized by the at-risk criteria are already ill and do not only need preventive intervention but also treatment. As is indicated by a recent study successfully using omega-3 fatty acids for both purposes, it may be promising to develop and investigate interventions especially for the at-risk state, independent of their effectiveness in manifest disease states. An overview on the current findings and ongoing research in this area is provided.
Similar content being viewed by others
References
Amminger GP, Schafer MR, Papageorgiou K et al (2010) Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 67:146–154
APA (2010) DSM-V development: proposed draft revisions to DSM disorders and criteria. http://www.dsm5.org/ProposedRevisions/Pages/proposedrevision.aspx? rid = 412. Accessed 8 July 2010
Bechdolf A, Ruhrmann S, Wagner M et al (2005) Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry Suppl 48:s45–s48
Bechdolf A, Veith V, Vogeley K et al (2008) PREVENT: background and rational of a clinical study comparing the preventive effects of CBT, aripriprazole and placebo in persons at-risk for psychosis. Early Interv Psychiatry 2(Suppl 1):11
Berger G, Wood S, Ross M et al (2008) Neuroprotective effects of low dose lithium in individuals at ultra-high risk for psychosis. Early Interv Psychiatry 2:A28
Cornblatt BA, Lencz T, Smith CW et al (2007) Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 68:546–557
Fusar-Poli P, Valmaggia L, McGuire P (2007) Can antidepressants prevent psychosis? Lancet 370:1746–1748
Häfner H, an der Heiden W (2008) Course and Outcome. In: Mueser KT, Jeste DV (eds) Clinical handbook of schizophrenia. The Guilford Press, New York, NY, pp 100–113
Haynes RB, Sackett DL, Guyatt GH et al (2006) Clinical epidemiology. Lippincott Williams & Williams, Philadelphia
Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276
Klosterkötter J (2008) Indicated prevention of schizophrenia. Dtsch Arztebl Int 105:532–539
Klosterkötter J, Hellmich M, Steinmeyer EM et al (2001) Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiat 58:158–164
Kuipers E, Bebbington P (2006) Cognitive behaviour therapy for psychosis. Epidemiol Psichiatr Soc 15:267–275
Kumra S, Oberstar JV, Sikich L et al (2008) Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 34:60–71
McGlashan TH, Zipursky RB, Perkins D et al (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiat 163:790–799
McGorry PD, Hickie IB, Yung AR et al (2006) Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 40:616–622
McGorry PD, Nelson B, Amminger GP et al (2009) Intervention in individuals at ultra high risk for psychosis: a review and future directions. J Clin Psychiatry 70:1206–1212
McGorry PD, Yung AR, Phillips LJ et al (2002) Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiat 59:921–928
Moreno C, Arango C, Parellada M et al (2007) Antidepressants in child and adolescent depression: where are the bugs? Acta Psychiat Scand 115:184–195
Morrison AP, French P, Bentall RP et al (2008) Early detection and psychological intervention using cognitive therapy for individuals at high risk of psychosis EDI2: baseline characteristics. Early Interv Psychiatry 2:A15
Morrison AP, French P, Parker S et al (2007) Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr Bull 33:682–687
Morrison AP, French P, Walford L et al (2004) Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Brit J Psychiat 185:291–297
Nuechterlein KH (1987) Vulnerability models for schizophrenia: State of the art. In: Häfner H, Gattaz WF, Janzarik W (eds) Search for the causes of schizophrenia. Springer, Heidelberg, pp 297–316
O’Brien MP, Zinberg JL, Bearden CE et al (2007) Psychoeducational multi-family group treatment with adolescents at high risk for developing psychosis. Early Interv Psychiatry 1:325–332
O’Brien MP, Zinberg JL, Ho L et al (2009) Family problem solving interactions and 6-month symptomatic and functional outcomes in youth at ultra-high risk for psychosis and with recent onset psychotic symptoms: a longitudinal study. Schizophr Res 107:198–205
Papakostas GI (2008) Tolerability of modern antidepressants. J Clin Psychiatry 69(Suppl E1):8–13
Phillips LJ, McGorry PD, Yuen HP et al (2007) Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr Res 96:25–33
Phillips LJ, Nelson B, Yuen HP et al (2009) Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. Aust N Z J Psychiat 43:818–829
Rietdijk J, Dragt S, Klaassen R et al (2010) A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an At Risk Mental State for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial. Trials 11
Ruhrmann S, Bechdolf A, Kuhn KU et al (2007) Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl 51:S88–S95
Ruhrmann S, Schultze-Lutter F, Klosterkötter J (2010) Probably at-risk, but certainly ill—Advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res 120:23–37
Ruhrmann S, Schultze-Lutter F, Klosterkötter J (2003) Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry 36(Suppl 3):S162–S167
Ruhrmann S, Schultze-Lutter F, Salokangas RK et al (2010) Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 67:241–251
Schultze-Lutter F, Ruhrmann S, Berning J et al (2010) Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr Bull 36:182–191
Schultze-Lutter F, Ruhrmann S, Klosterkötter J (2006) Can schizophrenia be predicted phenomenologically? In: Johannesen JO, Martindale BV, Cullberg J (eds) Evolving psychosis: different stages, different treatments. Routledge, Hove, pp 104–123
Simon AE, Dvorsky DN, Boesch J et al (2006) Defining subjects at risk for psychosis: a comparison of two approaches. Schizophr Res 81:83–90
Svirskis T, Korkeila J, Heinimaa M et al (2005) Axis-I disorders and vulnerability to psychosis. Schizophr Res 75:439–446
HO W (2004) Prevention of mental disorders : effective interventions and policy options. World Helath Organization, Geneva
Wood SJ, Berger GE, Dell’Olio M et al (2007) Effects of low dose lithium on hippocampal neuropathology in people at ultra-high risk for psychosis. Biol Psychiat 61:259s–260s
Woods SW, Breier A, Zipursky RB et al (2003) Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiat 54:453–464
Woods SW, Tully EM, Walsh BC et al (2007) Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry Suppl 51:s96–s101
Woods SW, Walsh B, Pearlson GD et al (2006) Glycine treatment of prodromal symptoms. Schizophr Res 86(Suppl):S7
Conflict of interest
S. Ruhrmann received speaker’s honoraria from AstraZeneca, Bristol-Myers Squibb, Essex and Janssen-Cilag. F. Schultze-Lutter declares that she has no conflict of interest. A. Bechdolf received speaker’s honoraria AstraZeneca, Bristol-Myers Squibb and Janssen-Cilag. J. Klosterkötter received speaker’s honoraria from AstraZeneca, Bristol-Myers Squibb and Janssen-Cilag, is member of the expert advisory board of Janssen-Cilag Germany and received a research grant from Bristol-Myers Squibb.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ruhrmann, S., Schultze-Lutter, F., Bechdolf, A. et al. Intervention in at-risk states for developing psychosis. Eur Arch Psychiatry Clin Neurosci 260 (Suppl 2), 90–94 (2010). https://doi.org/10.1007/s00406-010-0139-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00406-010-0139-5